Development of an unsupervised pixel-based clustering algorithm for compartmentalization of immunohistochemical expression using automated quantitative analysis

Applied Immunohistochemistry and Molecular Morphology

Volumn 17, Issue 4, 2009, Pages 329-337

  Gustavson, Mark D ^a   Bourke Martin, Brian ^a   Reilly, Dylan M ^a   Cregger, Melissa ^a   Williams, Christine ^a   Tedeschi, Greg ^a   Pinard, Robert ^a   Christiansen, Jason ^a  

^a HistoRx   (United States)

Author keywords

Biomarkers; Quantitative immunohistochemistry; Unsupervised image analysis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; TUMOR MARKER;

ACCURACY; ALGORITHM; ARTICLE; AUTOMATION; BREAST CANCER; CANCER SURVIVAL; CELL COMPARTMENTALIZATION; CELL MEMBRANE; CONTROLLED STUDY; CYTOPLASM; FLUORESCENCE HISTOCHEMISTRY; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REPRODUCIBILITY;

ALGORITHMS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; NEOPLASMS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 68149165758     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e318195ecaa     Document Type: Article

References (19)

1. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med. 2002;8:1323-1327. (Pubitemid 35373567)
2. Berger AJ, Camp RL, Di Vito KA, et al. Automated quantitative analysis of HDM2 expression in malignant melanoma shows association with early-stage disease and improved outcome. Cancer Res. 2004;64:8767-8772. (Pubitemid 39552095)
3. Camp RL, Dolled-Filhart M, King BL, et al. Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Res. 2003;63:1445-1448. (Pubitemid 36373626)
4. Dolled-Filhart M, Camp RL, Kowalski DP, et al. Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. Clin Cancer Res. 2003;9:594-600. (Pubitemid 36182589)
5. McCabe A, Dolled-Filhart M, Camp RL, et al. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst. 2005;97:1808-1815. (Pubitemid 43033901)
6. Miller DJ, Wang Y, Kesidis G. Emergent unsupervised clustering paradigms with potential application to bioinformatics. Front Biosci. 2008;13:677-690. (Pubitemid 351606122)
7. Dolled-Filhart M,McCabe A, Giltane J, et al. Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res. 2006;66:5487-5494.
8. Giltnane JM, Rimm DL. Technology insight: identification of biomarkers with tissue microarray technology. Nat Clin Pract Oncol. 2004;1:104-111. (Pubitemid 40823750)
9. Cregger M, Berger AJ, Rimm DL. Immunohistochemistry and quantitative analysis of protein expression. Arch Pathol Lab Med. 2006;130:1026-1030. (Pubitemid 44061434)
10. Jain A, Murty NM, Flynn PJ. Data clustering: a review. ACM Comput Surv. 1999;31:264-323.
11. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bioinformatics tool for biomarker assessment and outcome-based cutpoint optimization. Clin Cancer Res. 2004;10:7252-7259. (Pubitemid 39487712)
12. Raeside DE. Monte Carlo principles and applications. Phys Med Biol. 1976;21:181-197.
13. Khan MZ, Haleem A, Al Hassani H, et al. Cytopathological grading, as a predictor of histopathological grade, in ductal carcinoma (NOS) of breast, on air-dried Diff-Quik smears. Diagn Cytopathol. 2003;29:185-193. (Pubitemid 37193644)
14. Hsu CY, Kurman RJ, Vang R, et al. Nuclear size distinguishes lowfrom high-grade ovarian serous carcinoma and predicts outcome. Hum Pathol. 2005;36:1049-1054. (Pubitemid 41443255)
15. Osborne CK, Fisher E, Redmond C, et al. Estrogen receptor, a marker for human breast cancer differentiation and patient prognosis. Adv Exp Med Biol. 1981;138:377-385.
16. Bardou VJ, Arpino G, Elledge RM, et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003;21:1973-1979. (Pubitemid 46606386)
17. Hynes NE. Amplification and overexpression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. Semin Cancer Biol. 1993;4:19-26.
18. Simon GR, Sharma S, Cantor A, et al. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest. 2005;127:978-983. (Pubitemid 40775532)
19. Sano T, Lin H, Chen X, et al. Differential expression of MMAC/ PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res. 1999;59:1820-1824. (Pubitemid 29186149)